Kailera reported early Phase 1 dosing results for its investigational triple-hormone obesity drug KAI-4729, showing double-digit weight loss in a small China study. The company said a cohort of 12 participants lost up to 16% of body weight over 12 weeks as dose escalation progressed from 2 mg weekly to 12 mg. The readout adds to a growing competitive set of incretin and multi-agonist programs, with Kailera pointing to favorable comparisons versus early data disclosed by competitors targeting similar pathways. Kailera has said its own Phase 1 program outside China is planned for later, with data expected in 2027, while Hengrui is moving KAI-4729 into Phase 2 in China. The update arrives after Kailera’s IPO funding, which is positioned to support development through multiple trials. The company’s results reinforce investor focus on early efficacy signals that can de-risk selection of doses and partners for pivotal studies in a crowded weight-loss market.